TOP TEN perturbations for 1552908_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552908_at
Selected probe(set): 1552908_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552908_at (1552908_at) across 6673 perturbations tested by GENEVESTIGATOR:

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):3.755577
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):3.6359596
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):3.5854092
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

hypoxia study 11 (HK2) / control HK2 cell sample (normoxia)

Relative Expression (log2-ratio):2.1665292
Number of Samples:3 / 6
Experimental hypoxia study 11 (HK2)
Proximal tubule epithelial cell line HK-2 treated with hypoxia (1% O2) for 24 hours. HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control control HK2 cell sample (normoxia)
Proximal tubule epithelial cell line HK-2 treated with normoxia (20% O2) for 24 hours. HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.

atopic dermatitis study 20 (lesional; apremilast; 30mg; baseline) / atopic dermatitis study 20 (lesional; placebo; baseline)

Relative Expression (log2-ratio):-1.8765545
Number of Samples:7 / 6
Experimental atopic dermatitis study 20 (lesional; apremilast; 30mg; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before treatment with 30 mg of apremilast (at baseline). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) and use of biologics within 12 to 24 weeks of baseline.
Control atopic dermatitis study 20 (lesional; placebo; baseline)
Lesional skin biopsies isolated from patients with atopic dermatitis before placebo treatment (at baseline). Adult patients (both males and females; ≥18 years of age) with moderate to severe AD (documented for ≥ 12 months) were enrolled into study. Patients met Hanifin and Rajka criteria for AD at screening. They had AD that was not adequately controlled by a stable regimen (≥4 weeks) of topical corticosteroids or topical calcineurin inhibitors within 6 months of screening, or was considered inappropriate for topical therapy because of side effects or safety risks. Further patients' characteristics: AD-affected body surface area >10%, EASI score >12, and sPGA-A score >3. Patients were stratified by geographic region (North America and Japan) and within region. Exclusion criteria: a) significant or major uncontrolled disease; b) active or history of incompletely treated tuberculosis; c) history of malignancy within the past 5 years (except treated/cured squamous cell or basal cell in situ carcinomas or cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within 5 years prior to screening); d) unstable asthma; e) significant infection within 2 weeks of screening; f) active skin infection; g) use of phototherapy or systemic immunosuppressive drugs within 4 weeks; h) use of interferon-gama within 12 weeks; i) use of biologics within 12 to 24 weeks of baseline.

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.8073983
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.7990971
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

tumor supernatant activation study 3 / memory T-cell activation study 1

Relative Expression (log2-ratio):1.7494516
Number of Samples:4 / 3
Experimental tumor supernatant activation study 3
Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control memory T-cell activation study 1
Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.7404733
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.728735
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.